BiotechTube

insulin glargine + insulin glargine + insulin glargine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hyperglycemia

Conditions

Hyperglycemia, Diabetes

Trial Timeline

Jul 1, 2004 → May 1, 2005

NCT ID
NCT00338104

About insulin glargine + insulin glargine + insulin glargine

insulin glargine + insulin glargine + insulin glargine is a approved stage product being developed by Sanofi for Hyperglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00338104. Target conditions include Hyperglycemia, Diabetes.

What happened to similar drugs?

2 of 4 similar drugs in Hyperglycemia were approved

Approved (2) Terminated (2) Active (0)
✅Dapagliflozin + Sliding scale insulinAstraZenecaApproved
✅NPH insulin plus Complete Insulin Orders + Complete Insulin OrdersSanofiApproved
❌Human regular insulin + Insulin lispro + Insulin glargineEli LillyPhase 3
❌insulin glargine recombinant + therapeutic insulinSanofiPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00338104ApprovedCompleted

Competing Products

9 competing products in Hyperglycemia

See all competitors
ProductCompanyStageHype Score
Exenatide + InsulinEli LillyPhase 2/3
38
Human regular insulin + Insulin lispro + Insulin glargineEli LillyPhase 3
32
Dapagliflozin + Sliding scale insulinAstraZenecaApproved
43
GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200MerckPhase 1
29
liraglutide + placeboNovo NordiskPre-clinical
26
Olanzapine + ZiprasidonePfizerPre-clinical
26
NPH insulin plus Complete Insulin Orders + Complete Insulin OrdersSanofiApproved
43
Lantus® (insulin glargine)SanofiPhase 1
29
insulin glargine recombinant + therapeutic insulinSanofiPhase 3
32